Komori
Kringle Pharma (4884) · InitiativeFirst stated

Pre-Application Consultation for Orphan Drug Designation for Vocal Fold Scarring

First written in 2026-05-18. . Latest entry: 2026-05-18.

1entries
1years
1from disclosures
Share on X
How it moved
Same theme, other companies

This thread is not in a theme yet. When the same subject shows up in other companies' filings, you can compare them here.

Full recordFilings, disclosures and news, newest first
  1. 2026-05-18First statedEarnings presentation

    「引き続き、厚労省とはオーファン申請前の協議を続けております。」

    声帯瘢痕について、厚生労働省との希少疾病用医薬品指定申請前の協議継続を新たに確認した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Kringle Pharma yet. It last moved in the Earnings presentation of 2026-05-18: "First stated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Pre-Application Consultation for Orphan Drug Designation for Vocal Fold Scarring | Kringle Pharma,Inc. (4884) | Komori